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Introduction
Chronic pain is responsible for significant personal suffering worldwide [1] . Those with persistent disabling symptoms also contribute to substantial costs to society via health care expenses and reduced work productivity. For this reason, many treatment options have been developed and studied. Spinal cord stimulation (SCS) has been in use for more than five decades [2] for the treatment of chronic neuropathic pain conditions resistant to conventional pharmacological cognitive behavioral therapy or common invasive procedures. The action mechanism of SCS is poorly understood, but electrical activation of the large diameter afferents of the dorsal columns or dorsal roots appears to inhibit nociceptive small diameter afferent transmission, providing pain relief [3] . However, the treatment success is dependent on factors beyond the technical aspects of implantation. Even though a successful trial may be achieved initially, loss of pain relief can be experienced after 12 to 24 months [4, 5] . Loss of efficacy was usually attributed to technical factors (loss of target paresthesia) [5] , but more recently it has been suggested that the impact of psychological factors should be considered when investigating SCS efficacy [6] .
Psychological Factors and SCS
A large body of evidence suggests that specific cognitions and methods of coping can interact with the pain experience, impacting the response to pain and subsequent response to treatment [7] . Though it is clear that psychological factors may be associated with the outcomes and SCS international guidelines recommend that persons seeking SCS should undergo a comprehensive psychological assessment [8] , empirical studies cannot easily identify who will succeed or fail with SCS treatment. Psychological factors associated with a poor outcome following SCS include somatization, depression, anxiety and poor coping, drug addiction, and lack of social support [9] . A review identified depression as the strongest psychological predictor of an unsuccessful SCS [10] . However, excluding all patients with depression, anxiety, somatization, or a poor coping mechanism may be an overreaction: Chronic pain patients share these characteristics as a group, and SCS treatment may improve depression or anxiety [11] . Moreover, a high proportion of chronic pain patients have dysfunctional belief systems about their conditions and/or dysfunctional coping strategies to deal with their conditions. These beliefs and coping strategies can occur in the absence of a diagnosable psychiatric condition and can have a significant negative impact on the patients' response to treatment [12, 13] . It can therefore be hypothesized that certain psychological factors, specifically coping strategies, may interact with the experience of pain and the response to SCS. Evidence suggests that the adaptation strategy of patients with chronic pain is an ongoing process influenced by psychological factors. In particular, psychological flexibility [14] , coping strategies, depression, and internal control seem to be important factors in the development of persistent pain and disability [15] [16] [17] [18] [19] [20] .
According to the Multidimensional Pain Inventory (MPI) profile, patients classified as fitting the Adaptive Coping (AC) profile (e.g., problem-solving, including collecting information and refocusing on the problem, or regulation of emotion by focusing attention on the emotional response aroused by the stressor) show less pain, less depression, less functional impairment, and higher general self-efficacy, while the Dysfunctional (DYS) profile (i.e., avoidance, escape, catastrophizing) is correlated with reports of greater depression and affective distress, greater pain intensity and flare-up activity, greater functional impairment, and lower general self-efficacy. The third cluster, the Interpersonally Distressed (ID) profile, is mainly characterized by lower levels of perceived solicitous and distraction responses from the patients' partners or spouses and higher levels of punishing responses compared with the AC and DYS clusters [21, 22] .
As psychopathology alone has not proved a reliable indicator of SCS outcome, our study wanted to investigate patients' psychological characteristics as they relate to the effectiveness of SCS. Results suggest that a better knowledge of patients' characteristics could help the development of more effective treatments. We analyzed MPI profile as an indicator of successful SCS in long-term pain relief, which is particularly notable in that 36 months' follow-up is uncommon in chronic pain studies. We also used a measure of psychiatric disorders according to Diagnostic and Statistical Manual of Mental disorders -Text Revision DSM-IV TR criteria to compare which variables, coping strategies, or psychiatric disorders were likely to predict SCS effectiveness.
Methods

Study Design
This observational retrospective study was designed to evaluate specific presurgical psychological conditions as predictors of a negative or positive SCS treatment outcome. All study subjects were in treatment for their chronic disease at the Pain Management Unit of Santa Chiara University Hospital of Pisa and were recruited in the period between 2008 and 2013. Patients were assessed by a multidisciplinary team and referred for SCS trial. A detailed evaluation using a variety of physical and psychological variables was performed before the SCS implant by a pain team that included pain medicine consultants (GD, LT, FB, AM), a clinical psychologist (MP), and a neurosurgeon (AD). All patients completed a psychological assessment (MPI and Mini-International Neuropsychiatric Interview [MINI], see description below) within a month of trial implant (baseline). After 6, 12, 24, and 36 months following SCS implantation, patients underwent follow-up visits to check how SCS was working. During follow-up visits, intensity of pain measure was collected and used as an outcome measure.
Ethics approval from the Research Ethics Committee of Santa Chiara University Hospital was acquired before this study began. The study was explained, and a written informed consent was obtained from all participants.
Procedure and Patient Selection
Patients were assessed for eligibility based on inclusion and exclusion criteria. Key inclusion criteria were 1) age older than 18 years and 2) chronic intractable pain refractory to conservative therapy for longer than three months. Based on these criteria, SCS was indicated for 187 patients. Patients were excluded if 1) they were medically unfit for implant surgery, 2) they had unrealistic expectations of the treatment, 3) there was a lack of comprehension, 4) they had a secondary gain from the implant, 5) they had an active disruptive psychological or psychiatric disorder or other condition significant to impact perception of pain or treatment outcome. Following multidisciplinary team approval, 137 patients were referred for trial. Almost half were women (mean age ¼ 60.21 years), with the following indications for SCS implant: failed back surgery syndrome (51.1%), low back pain without surgery (27.5%), and other pathologies (21.4%, e.g., complex regional pain syndrome, postherpetic neuralgia, peripheral neuropathy). We collected data only from those patients without complications (e.g., lead dislocation, infections, etc.) that might have interfered with perception of SCS effectiveness.
Procedure
One octopolar lead was implanted percutaneously in the posterior spinal epidural space under radiographic imaging. All patients received a traditional SCS implant, and stimulation parameters were adjusted to optimally overlap paresthesia with the region of the subjects' pain intraoperatively. Consistent with clinical practice, subjects underwent a trial SCS phase lasting up to four weeks to determine short-term response. During the trial period, if a patient reports less than 50% pain relief, the electrical parameters are reprogrammed in order to achieve a better pain reduction. At the end of the trial period, if more than 50% pain relief is reported, the patient proceeds to having a fully implanted SCS. If less than 50% pain relief is reported, the lead is explanted.
Baseline Psychological Assessment
The Multidimensional Pain Inventory [23] is a brief but comprehensive measure of behavioral and psychological response to chronic pain experience viewed from a cognitive behavioral perspective. It has been translated into Italian [24] , attempting to reproduce the original factor structure of the MPI. The MPI, in its final form, is a 61-item inventory divided into three parts, each containing several subscales. The first part evaluates five important dimensions of the pain experience: perceived interference of pain in various areas of patients' functioning, support and concern of significant others, pain severity, self-control, and negative mood. Part II examines the responses of significant others to communications of pain. Three subscales measure the perceived frequency of punishing, solicitous, and distracting responses. The third part assesses the patients' report of their participation in four categories of common daily activities: household chores, outdoor work, activities away from home, and social activities. Time of administration is about 20 minutes.
Following Turk and Rudy [25, 26] , this study used three MPI distinct cluster profiles of patients who were labeled as Dysfunctional, Interpersonally Distressed, and Adaptive Copers. Patients' MPI responses were scored and classified using the computer program (MPI Software, version 3.0) developed by Rudy [27] . This computer program determines whether an individual's set of MPI scale scores are similar to any of the three prototypic patients' profiles [28] .
The MINI was applied as the structured diagnostic interview [29] for DSM-IV TR (American Psychiatric Association 1994) and International Classification of Disease (ICD-10) (World Health Organization 1993) assessing psychiatric disorders. The MINI is divided into modules identified by letters corresponding to diagnostic categories. It is based on "yes" and "no" answers and covers 14 Axis I disorders. In the multiaxial system of DSM-IV TR, Axis I disorders include all major mental disorders as well as developmental and learning disorders. With an administration time of approximately 15 minutes, it was designed to meet the need for a short but accurate structured psychiatric interview for clinical trials and epidemiology studies [29] .
Intensity of pain at baseline and at follow-ups was measured using a 10 cm VAS. The visual analog scale of pain has been used as a method to measure the amount of pain a patient feels. The VAS is a 100 mmlong horizontal line that contains a word description at each end ("no pain" to "worst imaginable pain"). The patient represents his perception of the amount of pain he feels by marking a horizontal line between two points. The VAS score is measured in mm from the left-hand end of the line to the point indicated by the patient.
Statistical Analysis
The primary aim of the study is to determine how strong pre-implantation factors are in predicting the outcome of the SCS implant. First, we analyze the proportion of chronic pain patients who show different pain behavior profiles. The MPI was used to characterize distinct psychosocial subgroups of patients with chronic pain: adaptive, dysfunctional, and interpersonally distressed. To study whether different pain behavior profiles determine differences in the outcome of SCS treatment, we divided our sample into three groups based on the outcome of SCS treatment: patients with at least three years' SCS treatment (long-term group [LT]), patients who decided to explant the trial device (trial explanters [TE]), and patients who decided to explant the permanent device (permanent explanters [PE]) due to a loss of pain relief. As psychiatric disorders are often a predictor of poor outcome, we used the MINI interview to determine the proportion of chronic pain patients who presented a psychiatric disorder. Subsequent analysis calculated the frequency of psychiatric disorders in the psychosocial MPI groups and how the presence of a psychiatric disorder might predict the outcome of an SCS implant.
The statistical analyses were performed using the Statistical Package for Social Sciences (SPSS), version 16.0. Potential differences across the groups in sociodemographic and clinical variables were explored by means of analysis of variance (ANOVA) for continuous variables. Normality tests were performed. Skewness and Kurtosis indexes for the main variables in the study follow between j2j, suggesting that the variables are normally distributed (MPI Skewness ¼ [30] . Logistic regression tests were then conducted to explore differences in MPI profile and psychiatric disorders between the SCS groups. Continuous variables with normal distribution are presented as mean 6 SD, and the comparison of means for such data (age of patients, intensity of pain, MPI scales) was performed by t test. Categorical data (MPI psychosocial groups, SCS outcome groups, and psychiatric disorders) were described as percentages and compared with the logistic regression test to find pre-implantation predictors. A P value of less than 0.05 was considered statistically significant.
Results
A total of 137 patients underwent a trial implant. A permanent implantable pulse generator (IPG) was implanted in 115 patients. Based on SCS implant outcomes collected during follow-up visits, patients were divided into three groups. As shown in the flow chart (Figure 1 ), 99 subjects had good pain relief and maintained the implant for three years after the implantation of permanent IPG (LT). Twenty-two subjects reported no pain relief during the trial stage (TE), and 16 reported a loss of pain relief after the permanent implant and decided to explant it (PE) (Figure 1) . Patients who decided to explant a permanent device were advised to turn the device off for a month before proceeding with the explant. In accordance with our clinical practice, when patients did not report any worsening of pain after a period when the device was off, we explanted the device. Patients reported a loss of pain relief and decided to explant consequently after an average period of 19.7 months. No technical problems due to IPG or lead justified the worsening of pain.
Groups did not differ in sociodemographic variables. Patients who decided to explant (trial and permanent IPG) reported no pain relief or a loss of pain relief and at the last follow-up visit before the explant showed a greater pain intensity that justified their decision (Table 1) . Study groups included patients with different diagnoses of chronic pain. As shown in Table 2 , our sample groups did not differ in pain intensity at baseline and follow-ups, and diagnoses were not correlated with the percentage of explants and strategies of coping.
According to MPI psychosocial groups in the total sample, 46.7% of subjects fit the AC profile, 41.9% of subjects fit the DYS profile, and 11.7% fit the ID profile. Logistic regression analysis revealed significant differences in MPI profile frequency among SCS outcome groups. An adaptive coping to pain contributed to SCS long-term pain relief (P < 0.0001) ( Table 3 ). Significant statistical differences were achieved for the presence (yes/no) of psychiatric disorders among SCS outcome groups. The presence of psychiatric disorders in the total sample was high. Pre-implantation psychological evaluation revealed that 43.3% of patients suffered from a psychiatric disorder according to DSM-IV TR criteria. Regression analysis revealed that the presence of psychiatric disorders, mood disorders, and anxiety disorders contributed significantly to an unsuccessful SCS treatment (P < 0.0001, P < 0.0001, and P ¼ 0.0005, respectively) ( Table 4 ). In particular, analysis revealed that anxiety was more frequent in patients who decided to explant the trial device (50%), while mood disorders were strongly associated with the decision to explant the permanent device (79.9%). Moreover, the presence of psychiatric disorders was strongly associated with a maladaptive coping to pain. Regression analysis showed that ID and DYSF coping groups showed a higher presence of mood disorders (37.5% and 40.3%, respectively) and anxiety disorders (12.5% and 26.3%, respectively) when compared with the AC group (Table 5) .
Discussion
This is the first study to investigate whether psychological/behavioral profiles classified according to the MPI instrument are associated with SCS outcome. SCS may be efficacious for chronic pain, but as many as 30% of spinal cord stimulation patients fail to obtain long-term pain relief, even with the strictest parameters of a successful trial and ideal placement of the permanent device [9] . Some previous investigators have found that psychological variables can influence the results of the SCS implant [31] . The current study supports these findings. The objective of pretrial implant assessment was to determine which psychological and behavioral factors were involved in a successful pain management treatment. Comparison of groups revealed that some variables of interest were significant. In previous studies about MPI profiles, DYS and ID patients scored high on pain severity, life interference, and emotional distress, but low on perceived control and activity. On the contrary, AC patients showed low levels of pain interference and distress, but high levels of life control and activity. The cluster profiles have been replicated across different patient groups with temporomandibular disorders, low back pain, headache, and fibromyalgia [25] [26] [27] . Additional research suggests the generalizability of the cluster profiles by using different measures of the constructs assessed by the MPI scales [32, 33, 34] .
Recent studies [35, 36] have supported the predictive validity of the MPI subgroups regarding treatment outcome. In line with the findings in this study, MPI profiles had a different treatment outcome. Specifically, we found that AC patients fare better than DYS and ID patients. Our first line of evidence pertained to SCS outcome. Most of patients with a better long-lasting result (good pain relief after three years from the permanent implant) fit an AC profile (58.6%). Differences with the SCS outcome were found between the ID and DYS groups. People in the DYS cluster reported a higher level of psychiatric disorders and were more likely to explant the trial implant; on the contrary, the ID pattern of MPI was more frequent in people who decided to explant the permanent device (PE group). In the long term, lack of social support and a punishing response to pain seem to influence the perception of SCS effectiveness. Discordant relationships with significant others might worsen depression symptoms and alter perception of pain. Remarkably, the patients' grouping could not be explained by chronicity and was unrelated to age, gender, education, or pain type, but rather appeared to reflect individual differences in managing a stressful chronic condition. The MPI instrument showed great advantages. The questionnaire successfully classified subjects according to psychological and behavioral subgroup profiles associated with SCS outcome. This information may be clinically relevant for other aspects of the patients' encounters, such as the indication for comanagement with other health professionals (e.g., psychologists) for the DYS individuals or involving significant others (spouse, relative, friends) in the treatment plan for the ID patients. Identified higher-risk profile patients could reduce the long-term failed group as MPI could be used as an indicator for a pre-implant psychological therapy referral.
Anxiety and depression are known to be associated with chronic pain, and they can influence the outcome of pain therapy [37, 38] . Frequent comorbidity of depression and chronic pain has inspired the formulation of a hypothesis regarding a shared neurobiological mechanism of both conditions. The bulk of evidence suggests that the pathophysiology of chronic pain and depression is closely coupled with the abnormal function of the brain networks involved in the regulation of both emotions and pain, and other mechanisms involved in these processes such as insufficiency of descending serotonin and noradrenaline pathways and abnormal activation of proinflammatory cytokines and substance P [39, 40] .
The present study denoted that psychiatric disorders can predict the outcome of SCS implant. In our sample, the presence of psychiatric disorders was found to be associated with SCS failure. In particular, most patients in the TE and PE groups showed a higher rate of mood and anxiety disorders than patients in the LT group. This finding is in line with previous studies that have observed that depression, anxiety, and somatization are associated with and impact the experience and perception of pain [10, 41] . A recent study confirmed that psychological aspects such as depression and autonomous coping may impact SCS treatment [6] . Our data fall in agreement with previous works as they identify depression as the main factor of both functional and emotional low adjustment [42] . The presence of depression predicts a maladaptive adjustment to chronic pain and a failure of subsequent chronic pain treatment. We can assume that depression influences the relationship between coping profile and outcome as a mediating variable. Cognitive distortions such as catastrophizing, typical of a depression state, might reinforce negative thoughts or emotions about chronic pain and lead to an unsuccessful treatment outcome. In this case, a person predicts that all things (for example, pain) are going to go wrong [43] .
In our sample, anxiety disorder was more frequent in the TE group. Anxiety is generally considered predictive of chronic postoperative pain [44] . In the case of an established chronic pain condition, the presence of anxiety disorders could intensify it when patients undergo a surgical procedure such as SCS implant, leading to a failure of SCS treatment, especially in the trial period.
This study shows different limitations. Intensity of pain was the only outcome measure. We did not assess changes in disability or pharmacological therapy. In our sample, psychiatric disorders predicted an unsuccessful SCS treatment; however, a recent systematic review of psychological characteristics impacting SCS suggested that depression following the onset of pain may not be a complete contraindication for SCS [7] . We did not assess onset of the patients' depression/anxiety. Premorbid psychopathology to the onset of pain may reduce the effectiveness of SCS, whereas psychopathology as a temporary personality feature in response to environmental circumstances may not as symptoms could improve with a successful SCS.
Results showed that 25.3% of the LT group had mood or anxiety disorders and 12.9% of the AC group had a DSM diagnosis. As MINI led to a categorical diagnosis (yes/not), we didn't have information about the severity of psychopathology. Depression and/or anxiety may impact the long-term effectiveness of SCS. On the other hand, depression and/or anxiety should not be considered contraindicative for implantation as it may improve with successful SCS [9, 45] . Further investigation is needed. In the present study, SCS outcome groups differed in number. This could be a limitation for the statistical analysis and the significance of the results. After the multidisciplinary screening, we did not include patients with unrealistic expectations and severe psychiatric disorders; even the inclusion of these patients could potentially lead to identification of stronger psychological predictors of SCS implant, which is not recommended considering the invasiveness of therapy and unlikely patient benefit.
The use of pre-implantation factors to predict the outcome of SCS has yet to be developed as a robust tool.
Results of this study contribute to a further understanding of these factors, however. In view of the Neuromodulation Appropriate Consensus Committee recommendations (NACC 2014) to perform a study about psychological predictors of spinal cord stimulation, it would be of value to evaluate onset, severity of psychopathology, and psychological factors related to mental/emotional adjustment to chronic pain to determine the impact of psychological variables on SCS treatment outcome.
Conclusions
Psychological factors identified in previous publications (anxiety and depression) were found to be associated with SCS outcome, but the findings of the present study go further, and they may be seen as supportive of a biopsychosocial perspective of chronic pain. All patients represent a complex of biological, social, and psychological disorders. Each of these factors cannot be considered in isolation: Each element interacts with and is affected by each other element. SCS psychological screening should consider the multitude of factors contributing to the pain persistence and develop pathways that include referral threshold to psychology session to reduce the magnitude of factors associated with a suboptimal SCS outcome. In this study, MPI coping profile appears to be associated with long-term SCS effectiveness. This suggests that a better knowledge of patients' characteristics could help the development of more effective treatments. A multidisciplinary rehabilitation program for patients with poor coping strategies and enduring psychopathology prior to implant may prove efficacious to long-term SCS outcome, changing pain belief, and coping strategies [46] . This study also indicates the value of monitoring each patient's progress following standard pain clinic treatment, encouraging completion of validated self-report questionnaires covering a range of domains at regular intervals.
Positive Clinical Implications
Results suggested that the MPI could be considered a valid instrument to assess patients before the implant, collecting physical, psychosocial, and behavioral information that might interfere with effective pain management. Exploring the coping profile and not just psychiatric disorders during SCS screening helps to identify patients with a subthreshold psychopathology not detected by anxiety and depression questionnaires.
